Product Center
The Launch Meeting of the Phase III Clinical Trial of the Quadrivalent Influenza Virus Subunit Vaccine (Ages 6–35 Months) Was Successfully Completed
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-02-04
- Views:
(Summary description)As the old year concludes with splendid achievements, the new year begins with renewed progress! On January 31st, the kick-off meeting for the Phase III clinical trial of Ab&B Bio-Tech Co., Ltd. JS’s quadrivalent influenza virus subunit vaccine (ages 6–35 months) was held at the Henan clinical research site. This marks another Phase III clinical trial following the successful completion of the quadrivalent influenza virus subunit vaccine (ages 3 and above) Phase III trial.
The Launch Meeting of the Phase III Clinical Trial of the Quadrivalent Influenza Virus Subunit Vaccine (Ages 6–35 Months) Was Successfully Completed
(Summary description)As the old year concludes with splendid achievements, the new year begins with renewed progress! On January 31st, the kick-off meeting for the Phase III clinical trial of Ab&B Bio-Tech Co., Ltd. JS’s quadrivalent influenza virus subunit vaccine (ages 6–35 months) was held at the Henan clinical research site. This marks another Phase III clinical trial following the successful completion of the quadrivalent influenza virus subunit vaccine (ages 3 and above) Phase III trial.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2023-02-04 16:17
- Views:
As the old year concludes with splendid achievements, the new year begins with renewed progress! On January 31st, the kick-off meeting for the Phase III clinical trial of Ab&B Bio-Tech Co., Ltd. JS’s quadrivalent influenza virus subunit vaccine (ages 6–35 months) was held at the Henan clinical research site. This marks another Phase III clinical trial following the successful completion of the quadrivalent influenza virus subunit vaccine (ages 3 and above) Phase III trial.
This clinical trial is a randomized, blinded, active-controlled Phase III study to evaluate the safety and immunogenicity of the quadrivalent influenza virus subunit vaccine in healthy participants aged 6–35 months. The objective is to verify the efficacy and safety of the vaccine in this pediatric population.Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us